Tofersen (BIIB067) is being evaluated in a Phase 3 trial for its efficacy in presymptomatic adults carrying SOD1 mutations, a significant genetic contributor to amyotrophic lateral sclerosis (ALS). The market for ALS therapies is expanding, with increasing interest in genetic and targeted treatments. The trial's focus on presymptomatic patients may position Tofersen as a first-in-class therapy, potentially leading to a competitive advantage in a niche segment of the ALS market. The successful outcome of this trial could enhance Biogen's portfolio and provide a significant revenue stream, particularly given the unmet medical need in this patient population. However, the competitive landscape includes existing ALS therapies like riluzole and edaravone, as well as emerging gene therapies, necessitating careful monitoring of market dynamics and competitor developments.